The GLP-1 market is evolving rapidly, with innovation driving progress while introducing new clinical and regulatory challenges specially around compounded formulations and reimbursement limitations
Studies by Greenwood-Van Meerveld and colleagues using rodent POI models demonstrated that ipamorelin produced dose-dependent improvements in gastric emptying and reversal of POI-induced delayed gastrointestinal transit, with effects mediated through GHS-R1a expressed in gastrointestinal smooth muscle and enteric nervous system tissue
Some of its reserves are present in skeletal muscles, but also in the liver and kidneys
In contrast, indirect effects might occur through changes in body weight, energy levels, mood, or other factors that can secondarily influence sexual function
Some older GLP-1 drugs have been discontinued or removed from the market, but the drug class remains very active
They will adjust the dosage according to your bodys response and the severity of side effects